Reporter brief
COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract does not report what outcomes were measured or what the actual results were, making it impossible to determine whether fisetin had any effect on disease progression or inflammation.
- Sample size is not reported, limiting assessment of statistical power.
- Only a Phase 2 pilot study in hospitalized patients; results would not establish efficacy in other populations or settings.
Study design and sample
Rct; Human.
Hospitalized adults with SARS-CoV-2
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Oct 14, 2025
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.